Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2.

Bone morphogenic protein-2 (BMP-2) is a member of the transforming growth factor beta (TGF-beta) superfamily. While BMP-2 is capable of inducing bone formation ectopically, little is known about its role on osteoclastogenesis. In this study, we examined the effect of BMP-2 on osteoclast-like multinucleated cell (OCL) formation in cocultures of osteoblast-like cells and hematopoietic cells of bone marrow origin. BMP-2 alone did not stimulate OCL formation in this culture system; however, it strongly enhanced OCL formation in a dose-dependent fashion in the presence of interleukin-1alpha (IL-1alpha). Western blot analysis showed that a simultaneous addition of BMP-2 and IL-1alpha synergistically enhanced cyclooxygenase-2 (COX-2) expression in osteoblast-like cells. Moreover, Northern blot analysis revealed that the level of osteoclast differentiation factor (ODF) mRNA increased by treatment with BMP-2 and IL-1alpha in osteoblast-like cells. It is noted that BMP-2 alone did cause an increase in the expression of both COX-2 and ODF genes. The stimulatory effect of BMP-2 was abolished by adding nonsteroidal anti-inflammatory drugs, such as indomethacin and a selective COX-2 inhibitor NS-398. Addition of NS-398 inhibited the expression of the ODF gene in osteoblast-like cells treated with BMP-2 and IL-1alpha. These results indicated that the combination of BMP-2 and IL-1alpha stimulated osteoblast-like cells to elevate the expression of both COX-2 and ODF genes, resulting in an enhanced OCL formation. Since BMP-2 alone induced the expression of COX-2 and ODF genes in osteoblast-like cells, it appears to be one of the regulating factors of osteoclastogenesis.

[1]  N. Udagawa,et al.  Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. , 1998, Biochemical and biophysical research communications.

[2]  N. Udagawa,et al.  Role of prostaglandins in interleukin‐1‐induced bone resorption in mice in vitro , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[4]  P. Lehenkari,et al.  Effects of recombinant human osteogenic protein-1 on the differentiation of osteoclast-like cells and bone resorption. , 1995, Biochemical and biophysical research communications.

[5]  N. Udagawa,et al.  Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. , 1998, Biochemical and biophysical research communications.

[6]  N. Takahashi,et al.  Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  K. Chihara,et al.  Stimulatory effect of bone morphogenetic protein‐2 on osteoclast‐like cell formation and bone‐resorbing activity , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  M. Hirafuji,et al.  Activin enhances osteoclast-like cell formation in vitro. , 1993, Biochemical and biophysical research communications.

[9]  A. Reddi BMPs: Actions in flesh and bone , 1997, Nature Medicine.

[10]  T. Martin,et al.  Modulation of osteoclast differentiation. , 1992, Endocrine reviews.

[11]  D. Tatakis Interleukin-1 and bone metabolism: a review. , 1993, Journal of periodontology.

[12]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[13]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  V. Rosen,et al.  Novel regulators of bone formation: molecular clones and activities. , 1988 .

[15]  N. Nagata,et al.  Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells , 1998 .

[16]  T. Martin,et al.  A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. , 1998, Endocrinology.

[17]  K. Ikeda,et al.  Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells* , 1998, The Journal of Biological Chemistry.

[18]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[19]  G. Rodan,et al.  Biphasic effects of transforming growth factor-beta on the production of osteoclast-like cells in mouse bone marrow cultures: the role of prostaglandins in the generation of these cells. , 1990, Endocrinology.

[20]  Roodman Gd Advances in bone biology: the osteoclast. , 1996, Endocrine reviews.

[21]  Sheila J. Jones,et al.  Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. , 1988, Endocrinology.

[22]  E. Jimi,et al.  Specific Inhibitors of Vacuolar H+‐ATPase Trigger Apoptotic Cell Death of Osteoclasts , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  B. Hogan,et al.  Bone morphogenetic proteins: multifunctional regulators of vertebrate development. , 1996, Genes & development.